Treatment with amisulpride and olanzapine improve neuropsychological function in schizophrenia

被引:24
作者
Mortimer, Ann M.
Joyce, Eileen
Balasubramaniam, Krishnapillai
Choudhary, Prasoon C.
Saleem, Packeeruther T.
机构
[1] Univ Hull, Dept Psychiat, Kingston Upon Hull HU6 7RX, N Humberside, England
[2] UCL, Inst Neurol, London, England
[3] Calnwood Court, Luton, Beds, England
[4] Queens Pk Hosp, Blackburn, Lancs, England
关键词
amisulpride; olanzapine; schizophrenia; cognitive function; neuropsychological testing;
D O I
10.1002/hup.865
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Objectives Although antipsychotic drugs control acute psychotic manifestations of schizophrenia, improving cognitive symptoms is also important for long-term prognosis. Methods Three hundred and seventy-seven adult patients with acute psychosis were randomised to either amisulpride (200-800 mg/d) or olanzapine (5-20 mg/d) for 6 months. Neuropsychological performance was assessed at inclusion and after 6 months in a subgroup of 26 subjects (I I treated with amisulpride and 15 with olanzapine) using the Auditory Verbal Learning Test (AVLT), the Trail Making Test (TMT) and the Controlled Oral Word Association Test (COWAT). Results The improvement in BPRS score was similar in both treatment groups. No significant differences in test performance between groups were observed at inclusion. After 6months, AVLT scores increased by 8.7 points in the amisulpride group and by 2.3 points in the olanzapine group (p = 0.049). Completion speed in the TMT increased by 17.4 s (amisulpride) and 15.4 s (olanzapine) for Part A and by 39.8 and 48.8 s, respectively for Part B. Performance in the COWAT improved little in both groups. Conclusions Both amisulpride and olanzapine produce sustained improvement in certain measures of neuropsychologlical performance in patients with schizophrenia; a significant improvement in score on the AVLT was observed only with amisulpride. Copyright (c) 2007 John Wiley & Sons, Ltd.
引用
收藏
页码:445 / 454
页数:10
相关论文
共 52 条
[41]  
REITAN R. M., 1958, PERCEPT MOT SKILLS, V8, P271
[42]  
REY A, 1964, EXAMEN CLIN PSCYHOL
[43]  
SAYKIN AJ, 1994, ARCH GEN PSYCHIAT, V51, P124
[44]  
SAYKIN AJ, 1991, ARCH GEN PSYCHIAT, V48, P618
[45]  
Schoemaker H, 1997, J PHARMACOL EXP THER, V280, P83
[46]   THE COST OF COGNITIVE IMPAIRMENT IN SCHIZOPHRENIA [J].
SEVY, S ;
DAVIDSON, M .
SCHIZOPHRENIA RESEARCH, 1995, 17 (01) :1-3
[47]   Cognitive effects of olanzapine and clozapine treatment in chronic schizophrenia [J].
Sharma, T ;
Hughes, C ;
Soni, W ;
Kumari, V .
PSYCHOPHARMACOLOGY, 2003, 169 (3-4) :398-403
[48]   A Canadian multicenter trial assessing memory and executive functions in patients with schizophrenia spectrum disorders treated with olanzapine [J].
Stip, E ;
Remington, GJ ;
Dursun, S ;
Reiss, JP ;
Rotstein, E ;
MacEwan, GW ;
Chokka, PR ;
Jones, B ;
Dickson, RA .
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2003, 23 (04) :400-404
[49]   Are the cognitive effects of atypical antipsychotics influenced by their affinity to 5HT-2A receptors? [J].
Tyson, PJ ;
Roberts, KH ;
Mortimer, AM .
INTERNATIONAL JOURNAL OF NEUROSCIENCE, 2004, 114 (06) :593-611
[50]   SPECT imaging, clinical features, and cognition before and after low doses of amisulpride in schizophrenic patients with the deficit syndrome [J].
Vaiva, G ;
Thomas, P ;
Llorca, PM ;
Dupont, S ;
Cottencin, O ;
Devos, P ;
Mazas, O ;
Rascle, C ;
Steinling, M ;
Goudemand, M .
PSYCHIATRY RESEARCH-NEUROIMAGING, 2002, 115 (1-2) :37-48